SCHEMBL18987135

SCHEMBL18987135

CCCCCCc1cc(CCCCCC)cc(-n2c3ccccc3c3ccc(-c4ncc(-c5nc(-c6ccc(C(C)(C)C)cc6)nc(-c6ccc(C(C)(C)C)cc6)n5)c5ccccc45)cc32)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.32
TP53 P04637 2/20 0.32
TLR7 Q9NYK1 2/20 0.32
MAPT P10636 3/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 2/20 0.31
USP2 O75604 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TRPV1 Q8NER1 4/20 0.31
PIN1 Q13526 1/20 0.31
NPSR1 Q6W5P4 2/20 0.30
NPC1 O15118 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19006916 0.95 ADORA3 (0.34) ADORA3SMN1; SMN2TP53TLR7MAPT
SCHEMBL19001568 0.83 MAPT (0.36) SMN1; SMN2TP53MAPTKDM4EMEN1
SCHEMBL18987386 0.81 HSD11B1 (0.34) SMN1; SMN2TLR7MAPTKDM4EMEN1
SCHEMBL18987124 0.77 SMN1; SMN2 (0.32) ADORA3SMN1; SMN2TP53MAPTKDM4E
SCHEMBL19001567 0.76 HSD11B1 (0.34) SMN1; SMN2TP53TLR7MAPTKDM4E
SCHEMBL18987393 0.76 LPL (0.38) HSD11B1
SCHEMBL17691581 0.73 TP53 (0.43) SMN1; SMN2TP53MAPTKDM4EMEN1
SCHEMBL15887903 0.71 DHODH (0.43) SMN1; SMN2MAPTKDM4EMEN1KMT2A
SCHEMBL15887983 0.71 DHODH (0.43) SMN1; SMN2MAPTKDM4EMEN1KMT2A
SCHEMBL15248444 0.70 MAPT (0.43) SMN1; SMN2TP53MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11214585-B2 Light-emitting composition CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2022-01-04 US disclosed
EP-3390418-B1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECH LTD (GB) 2020-08-05 EP disclosed
US-20190002488-A1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2019-01-03 US disclosed
US-20190002629-A1 LIGHT-EMITTING COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2019-01-03 US disclosed
EP-3390418-A1 LIGHT-EMITTING COMPOUND Cambridge Display Technology Limited (GB) 2018-10-24 EP disclosed
EP-3390419-A1 LIGHT-EMITTING COMPOSITION Cambridge Display Technology Limited (GB) 2018-10-24 EP disclosed
WO-2017103584-A1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103586-A1 LIGHT-EMITTING COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103584-A1 LIGHT-EMITTING COMPOUND CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103586-A1 LIGHT-EMITTING COMPOSITION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214585-B2 Light-emitting composition CRY1, CRY2, ARL1 ADORA3 963/4885SMN1; SMN2 2193/4885TP53 3983/4885
US-20190002488-A1 LIGHT-EMITTING COMPOUND AR, ARL1, IK ADORA3 429/4885SMN1; SMN2 3472/4885TP53 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.